Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Christopher R. Bolen, Federico Mattiello, Michael Herold, Wolfgang Hiddemann, Sarah Huet, Wolfram Klapper, Robert Marcus, Farheen Mir, Gilles Salles, Oliver Weigert, Tina Nielsen, Mikkel Z. Oestergaard, Jeffrey M. Venstrom

Blood (2021) 137 (19): 2704–2707.

https://doi.org/10.1182/blood.2020008119

Published: 2021

Includes: Supplemental data

Journal Articles

Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

Lale Kostakoglu, MD MPH, Andrew Davies, MD PhD, Michael Herold, Wolfgang Hiddemann, Robert Marcus, Judith Trotman, FRACP, Andrea Knapp, Federico Mattiello, Tina G Nielsen, Deniz Sahin, Carol Ward, Anas Younes

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134784

Published: 2020

Journal Articles

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Lale Kostakoglu, MD MPH, Paola Berchialla, PhD, Federico Dalmasso, PhD, Larry A Pierce, PhD, Umberto Vitolo, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Tina G Nielsen, MD PhD, Christopher R Bolen, PhD, Deniz Sahin, BSc, Calvin Lee, MD, Tarec Christoffer C. El-Galaly, MD, Federico Mattiello, PhD, Paul E Kinahan, PhD, Stephane Chauvie, PhD

Blood (2019) 134 (Supplement_1): 883.

https://doi.org/10.1182/blood-2019-123450

Published: 2019

Journal Articles

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Donald Berry, PhD, Kristine Broglio, MS, Carol Ward, MSc, Federico Mattiello, PhD, Deniz Sahin, BSc, Tina G Nielsen, MD PhD, Anna McGlothlin, PhD, Corrine Elliott, MS, Thomas E. Witzig, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Maurizio Martelli, MD, Lale Kostakoglu, MD MPH, Grzegorz Nowakowski, MD

Blood (2019) 134 (Supplement_1): 4101.

https://doi.org/10.1182/blood-2019-124067

Published: 2019

Journal Articles

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lale Kostakoglu, MD MPH, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Andrea Knapp, PhD, Federico Mattiello, PhD, Tina G Nielsen, MD PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Carol Ward, MSc, Anas Younes, MD

Blood (2019) 134 (Supplement_1): 489.

https://doi.org/10.1182/blood-2019-123626

Published: 2019

Journal Articles

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Magdalena Klanova, Laurie H. Sehn, Isabelle Bence-Bruckler, Federica Cavallo, Jie Jin, Maurizio Martelli, Douglas Stewart, Umberto Vitolo, Francesco Zaja, Qingyuan Zhang, Federico Mattiello, Gila Sellam, Elizabeth A. Punnoose, Edith Szafer-Glusman, Christopher R. Bolen, Mikkel Z. Oestergaard, Guenter R. Fingerle-Rowson, Tina Nielsen, Marek Trneny

Blood (2019) 133 (9): 919–926.

https://doi.org/10.1182/blood-2018-07-862862

Published: 2019

Includes: Supplemental data

Journal Articles

A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Farheen Mir, MBBS, Andrew Grigg, Michael Herold, Wolfgang Hiddemann, Robert Marcus, John F. Seymour, MBBS, PhD, Christopher R Bolen, Andrea Knapp, Aino Launonen, Federico Mattiello, Tina Nielsen, Mikkel Z Oestergaard, Michael Wenger, Carla Casulo, MD

Blood (2018) 132 (Supplement 1): 2872.

https://doi.org/10.1182/blood-2018-99-114620

Published: 2018

Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study

Sally F Barrington, Judith Trotman, Deniz Sahin, David Belada, Andrew Davies, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Wolfgang Hiddemann, Robert Marcus, Tina Nielsen, Federico Mattiello, Harald Zeuner, Michel Meignan

Blood (2018) 132 (Supplement 1): 2882.

https://doi.org/10.1182/blood-2018-99-117235

Published: 2018

Journal Articles

Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials

Sarah C. Rutherford, Michael Herold, Wolfgang Hiddemann, Lale Kostakoglu, Robert Marcus, Maurizio Martelli, Laurie H Sehn, MDMPH, Marek Trněný, Judith Trotman, Umberto Vitolo, Tina Nielsen, Federico Mattiello, Deniz Sahin, Gila Sellam, Peter Martin, FRCPC, MD MS

Blood (2018) 132 (Supplement 1): 1605.

https://doi.org/10.1182/blood-2018-99-114913

Published: 2018

Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study

Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, MDMPH, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, MD, Yuankai Shi, Yoichi Tatsumi, Günter Fingerle-Rowson, Andrea Knapp, Federico Mattiello, Tina Nielsen, Gila Sellam, Denis Sahin, Umberto Vitolo, MD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 824.

https://doi.org/10.1182/blood.V130.Suppl_1.824.824

Published: 2017

Journal Articles

Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase 3 GOYA Trial

Mikkel Z. Oestergaard, Christopher Bolen, Federico Mattiello, Maurizio Martelli, Laurie H. Sehn, MDMPH, Marek Trněný, MD PhD, Alexandar Tzankov, Umberto Vitolo, MD, Tina Nielsen, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Georg Lenz

Blood (2017) 130 (Supplement 1): 1543.

https://doi.org/10.1182/blood.V130.Suppl_1.1543.1543

Published: 2017

Journal Articles

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Bruce D. Cheson, Marek Trněný, Kamal Bouabdallah, MD, Gregory Dueck, John Gribben, Pieternella J Lugtenburg, MD PhD, Oliver Press, Gilles A. Salles, Günter Fingerle-Rowson, Federico Mattiello, Elisabeth Wassner-Fritsch, Laurie H Sehn

Blood (2016) 128 (22): 615.

https://doi.org/10.1182/blood.V128.22.615.615

Published: 2016

NARROW

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study

Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials

Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study

Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase 3 GOYA Trial

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only